Ji Eun Eom
Bio: Ji Eun Eom is an academic researcher from Ewha Womans University. The author has contributed to research in topics: Medicine & Inflammation. The author has an hindex of 5, co-authored 5 publications receiving 111 citations.
TL;DR: Conjugated linoleic acid (CLA), an eighteen-carbon unsaturated fatty acid, was discovered as a μ-calpain-specific inhibitor and showed neuroprotective effects against neurotoxins such as H2O2 and Aβ1-42 in SH-SY5Y cells, and inhibited Aβ oligomerization/fibrillation and A β-induced Zona Occludens-1 degradation.
TL;DR: Two compounds, 7 and 11, showed enzyme inhibitory activities at the cellular level and displayed neuroprotective effects against oxidative stress-induced apoptosis in SH-SY5Y cells, a human neuroblastoma cell line.
TL;DR: A cobalt albumin binding (CAB) assay is developed to correct the flaws of the ACB test with improving the and precision and may be able to be used in developing a quality control method for albumin and its pharmaceutical formulations including albumin injections.
TL;DR: The result of the IMA level measurement in normal versus stroke rat serum suggests that the ACuB assay is likely to be a reliable and sensitive method for the detection of ischemic states.
Abstract: Myocardial ischemia (MI) induces many changes in the body, including pH decrease and electrolyte imbalance. No obvious symptoms of MI appear until irreversible cellular injuries occur. Since early treatment is critical for recovery from ischemia, the development of reliable diagnostic tool is demanded to detect the early ischemic status. Ischemia modified albumin (IMA), formed by cleavage of the last two amino acids of the human serum albumin (HSA) N-terminus, has been considered so far as the most trustworthy and accurate marker for the investigation of ischemia. IMA levels are elevated in plasma within a few minutes of ischemic onset, and may last for up to 6 h. In the present study, we developed a novel assay for the examination of IMA levels to ameliorate the known albumin cobalt binding (ACB) test established previously. We observed a stronger copper ion bound to the HSA N-terminal peptide than cobalt ion by HPLC and ESI-TOF mass spectrometric analyses. The copper ion was employed with lucifer yellow (LY), a copper-specific reagent to develop a new albumin copper binding (ACuB) assay. The parameters capable of affecting the assay results were optimized, and the finally-optimized ACuB assay was validated. The result of the IMA level measurement in normal versus stroke rat serum suggests that the ACuB assay is likely to be a reliable and sensitive method for the detection of ischemic states.
TL;DR: The results discovered implicated that chalcone analogues possessing proper size and functional groups can be a potential lead core for selective non-peptidic -calpain inhibitor.
Abstract: In order to extend the scaffold of non-peptidic calpain inhibitor, we have designed and synthesized 14 chalcone derivatives categorized into two groups based on their structures. Compounds 7 () and 8 () in group A were most selective -calpain inhibitor over cathepsins B and L. On the other hand, compound 14 possessing furan ring exhibited inhibitory activities for -calpain () as well as cathepsin B (). The results discovered implicated that chalcone analogues possessing proper size and functional groups can be a potential lead core for selective non-peptidic -calpain inhibitor. Furthermore, dual inhibitors for -calpain and cathepsin B can also be developed from chalcones by elaborate structure manipulation.
TL;DR: A comprehensive study on molecular targets/pathways involved in carcinogenesis, mechanism of actions (MOAs), structure activity relationships (SARs) and patents granted have been highlighted and may be helpful for (medicinal) chemists to design more potent, safe, selective and cost effective anti-cancer chalcones.
TL;DR: In this article, the synthesis of chalcones and their biological activities with focus on structure-activity relationships are discussed, and the properties, biosynthesis and structural diversity of natural chalcone are reviewed.
Abstract: Chalcone is an aromatic ketone that forms the central core of many important biological compounds, which are known as chalcones. Chalcones are the biogenetic precursors of flavonoids and isoflavonoids, which are abundant in plants. Chalcones are active lead molecules in medicinal chemistry for the discovery of new drugs. Here, we review properties, biosynthesis and structural diversity of natural chalcones. Then, we present the synthesis of chalcones and their biological activities with focus on structure–activity relationships. Pharmaceutically important and patented chalcones are also discussed.
TL;DR: A pharmacological review of their bioactive constituents and introducing the value of these nuts as the effective supplements and natural medicinal foods in AD patients is introduced, including almond, hazelnut and walnut.
TL;DR: An overview of serum albumin and different purification methods is summarized, which shows how many efforts have been accomplished to achieve albumin during a long period of time.
Abstract: As the most frequent plasma protein, albumin constitutes more than 50% of the serum proteins in healthy individuals. It has a key role in oncotic pressure maintenance and it is known as a versatile protein carrier for transportation of various endogenous and exogenous ligands. Reduced amounts of albumin in the body will lead to different kinds of diseases such as hypovolemia and hypoproteinemia. It also has various indications in shocks, burns, cardiopulmonary bypass, acute liver failure and etc. Further applications in research consist of cell culture supplement, drug delivery carrier and protein/drug stabilizer. So, the demand for albumin increased annually worldwide. Due to different applications of albumin, many efforts have been accomplished to achieve albumin during a long period of time. In this review, an overview of serum albumin and different purification methods are summarized.
TL;DR: Future perspectives for the global management of AD predict that genomics and proteomics may help in the search for reliable biomarkers, and the implementation of pharmacogenomic strategies will contribute to optimize drug development and therapeutics in AD and related disorders.
Abstract: Alzheimer's disease (AD) is a major problem of health and disability, with a relevant economic impact on our society. Despite important advances in pathogenesis, diagnosis, and treatment, its primary causes still remain elusive, accurate biomarkers are not well characterized, and the available pharmacological treatments are not cost-effective. As a complex disorder, AD is a polygenic and multifactorial clinical entity in which hundreds of defective genes distributed across the human genome may contribute to its pathogenesis. Diverse environmental factors, cerebrovascular dysfunction, and epigenetic phenomena, together with structural and functional genomic dysfunctions, lead to amyloid deposition, neurofibrillary tangle formation, and premature neuronal death, the major neuropathological hallmarks of AD. Future perspectives for the global management of AD predict that genomics and proteomics may help in the search for reliable biomarkers. In practical terms, the therapeutic response to conventional drugs (cholinesterase inhibitors, multifactorial strategies) is genotype-specific. Genomic factors potentially involved in AD pharmacogenomics include at least five categories of gene clusters: (1) genes associated with disease pathogenesis; (2) genes associated with the mechanism of action of drugs; (3) genes associated with drug metabolism (phase I and II reactions); (4) genes associated with drug transporters; and (5) pleiotropic genes involved in multifaceted cascades and metabolic reactions. The implementation of pharmacogenomic strategies will contribute to optimize drug development and therapeutics in AD and related disorders.